The Protective Effect of Staphylococcus epidermidis Biofilm Matrix against Phage Predation
Open Access
- 25 September 2020
- Vol. 12 (10), 1076
- https://doi.org/10.3390/v12101076
Abstract
Staphylococcus epidermidis is a major causative agent of nosocomial infections, mainly associated with the use of indwelling devices, on which this bacterium forms structures known as biofilms. Due to biofilms’ high tolerance to antibiotics, virulent bacteriophages were previously tested as novel therapeutic agents. However, several staphylococcal bacteriophages were shown to be inefficient against biofilms. In this study, the previously characterized S. epidermidis-specific Sepunavirus phiIBB-SEP1 (SEP1), which has a broad spectrum and high activity against planktonic cells, was evaluated concerning its efficacy against S. epidermidis biofilms. The in vitro biofilm killing assays demonstrated a reduced activity of the phage. To understand the underlying factors impairing SEP1 inefficacy against biofilms, this phage was tested against distinct planktonic and biofilm-derived bacterial populations. Interestingly, SEP1 was able to lyse planktonic cells in different physiological states, suggesting that the inefficacy for biofilm control resulted from the biofilm 3D structure and the protective effect of the matrix. To assess the impact of the biofilm architecture on phage predation, SEP1 was tested in disrupted biofilms resulting in a 2 orders-of-magnitude reduction in the number of viable cells after 6 h of infection. The interaction between SEP1 and the biofilm matrix was further assessed by the addition of matrix to phage particles. Results showed that the matrix did not inactivate phages nor affected phage adsorption. Moreover, confocal laser scanning microscopy data demonstrated that phage infected cells were less predominant in the biofilm regions where the matrix was more abundant. Our results provide compelling evidence indicating that the biofilm matrix can work as a barrier, allowing the bacteria to be hindered from phage infection.Keywords
Funding Information
- Horizon 2020 (Horizon 2020 research and innovation programme under grant agreement No. 713640)
- European Regional Development Fund (BioTecNorte operation (NORTE-01-0145-FEDER-000004))
This publication has 63 references indexed in Scilit:
- Comparison of RNA extraction methods from biofilm samples of Staphylococcus epidermidisBMC Research Notes, 2011
- Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in miceJCI Insight, 2011
- Vancomycin Susceptibility Trends and Prevalence of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in Clinical Methicillin-Resistant S. aureus IsolatesJournal of Clinical Microbiology, 2011
- Emergence of Pseudomonas aeruginosa Strains Producing High Levels of Persister Cells in Patients with Cystic FibrosisJournal of Bacteriology, 2010
- Economic burden of healthcare-associated infections: an American perspectiveExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- Staphylococcus epidermidis — the 'accidental' pathogenNature Reviews Microbiology, 2009
- Isolation and characterization of a T7-like lytic phage for Pseudomonas fluorescensBMC Biotechnology, 2008
- Medical biofilmsBiotechnology & Bioengineering, 2008
- The EPS Matrix: The “House of Biofilm Cells”Journal of Bacteriology, 2007
- Molecular Basis for Preferential Protective Efficacy of Antibodies Directed to the Poorly Acetylated Form of Staphylococcal Poly- N -Acetyl-β-(1-6)-GlucosamineInfection and Immunity, 2007